VOYAGER THERAPEUTICS INC. - COMMON STOCK

Voyager Reports Third Quarter 2025 Financial and Operating Results

10 ноя 2025 08:01:00 Источник Nasdaq GlobeNewswire

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

10 ноя 2025 08:01:00 Источник Nasdaq GlobeNewswire

Voyager to Present at Upcoming Investor Conferences

26 авг 2025 07:00:00 Источник Nasdaq GlobeNewswire

Voyager Reports Second Quarter 2025 Financial and Operating Results

06 авг 2025 16:01:00 Источник Nasdaq GlobeNewswire

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

16 июл 2025 07:00:00 Источник Nasdaq GlobeNewswire

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

10 июн 2025 07:00:51 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: VOYAGER THERAPEUTICS INC. - COMMON STOCK

30 май 2025 09:48:31 Источник NetDania Notify

NetDania - New 12 months Low: VOYAGER THERAPEUTICS INC. - COMMON STOCK

28 май 2025 14:51:04 Источник NetDania Notify

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

15 май 2025 07:00:31 Источник Nasdaq GlobeNewswire

Voyager Reports First Quarter 2025 Financial and Operating Results

06 май 2025 16:01:00 Источник Nasdaq GlobeNewswire

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

28 апр 2025 16:30:00 Источник Nasdaq GlobeNewswire

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

31 мар 2025 07:00:47 Источник Nasdaq GlobeNewswire

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

11 мар 2025 16:01:00 Источник Nasdaq GlobeNewswire

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

04 мар 2025 07:00:00 Источник Nasdaq GlobeNewswire

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

03 мар 2025 07:00:00 Источник Nasdaq GlobeNewswire

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

25 фев 2025 07:00:01 Источник Nasdaq GlobeNewswire

Voyager Provides Update on SOD1 ALS Gene Therapy Program

11 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire

Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference

06 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

20 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Voyager Reports Third Quarter 2024 Financial and Operating Results

12 ноя 2024 16:01:00 Источник Nasdaq GlobeNewswire